Lexicon Pharmaceuticals, Inc.
pilavapadin
diabetic peripheral neuropathic pain (DPNP)
Date
TBD
Advisory committee · Date TBD estimated
What's at stake
An FDA advisory committee reviews pilavapadin for diabetic peripheral neuropathic pain (DPNP) around Date TBD. The panel's public vote often front-runs the agency's final verdict — and the share price.
Primary source
· SEC 8-K
verified 13h ago
“The Company previously announced that the FDA raised no objections to the advancement of pilavapadin into Phase 3 development for diabetic peripheral neuropathic pain (DPNP).”